Evidence map›Paper›PMID 31197255›Full record

ArticleCellular & molecular immunology2020

Macrophages are the primary effector cells in IL-7-induced arthritis.

Seung-Jae Kim, Huan J Chang, Michael V Volin, Sadiq Umar, Katrien Van Raemdonck, Aimee Chevalier, Karol Palasiewicz, John W Christman, Suncica Volkov, Shiva Arami and 6 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cellular & molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02451748 (IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA), which is not on this map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02451748 phase4completednot on this map

IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2015 to 2017Enrolled32ConditionsRheumatoid ArthritisArmsLab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. The Role of Cytokines in Orthodontic Tooth Movement.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Seung-Jae KimDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
Huan J ChangDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
Michael V VolinDepartment of Microbiology and Immunology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, 60515, USA.
Sadiq UmarDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
Katrien Van RaemdonckDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
Aimee ChevalierDepartment of Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Karol PalasiewiczDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
John W ChristmanPulmonary, Critical Care and Sleep Medicine, Ohio State University Wexner Medical Center, Davis Heart and Lung Research Institute, Columbus, OH, 43210, USA.
Suncica VolkovDepartment of Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Shiva AramiDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
Mehrdad MazDivision of Allergy, Clinical Immunology and Rheumatology, The University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Anjali MehtaDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA.
Ryan K ZomorrodiDepartment of Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
David A FoxDivision of Rheumatology and Clinical Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, MI, 481096, USA.
Nadera SweissDepartment of Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Shiva ShahraraDivision of Rheumatology, Jesse Brown VA, Medical Center, Chicago, IL, 60612, USA. shahrara@uic.edu.
University of Illinois Chicago · USJesse Brown VA Medical Center · USMidwestern University · USThe Ohio State University Wexner Medical Center · USUniversity of Kansas Medical Center · USUniversity of Michigan–Ann Arbor · US

Funding

REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN ARDSR01HL137224 · NHLBI · OHIO STATE UNIVERSITY · PI CHRISTMAN, JOHN W, KARPURAPU, MANJULA · 2018 to 2025
$4.5M
Identifying a novel pathway that regulates RA immunometabolismR01AI167155 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHIVA SHAHRARA · 2022 to 2026
$2.9M
Identifying a novel link between two potent proangiogenic cascades in RAR03AR065778 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHAHRARA, SHIVA · 2014 to 2016
$239k
The Role of IL-17 in Monocyte MigrationR03AR056099 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHAHRARA, SHIVA · 2009 to 2011
$229k
Ligation of TLR7 promotes joint inflammation and bone loss in RA.I01BX002286 · VA · JESSE BROWN VA MEDICAL CENTER · PI SHAHRARA, SHIVA · 2015 to 2023
–
BLRD VA I01 BX002286NHLBI NIH HHS R01 HL137224NIAID NIH HHS R01 AI167155NIAMS NIH HHS R03 AR056099NIAMS NIH HHS R03 AR065778
6 · The paper itself

Abstract

Synovial macrophages are crucial in the development of joint inflammation and bone damage; however, the pathways that control macrophage remodeling in inflammatory M1 cells or bone-eroding osteoclasts are not fully understood. We determined that elevated IL-7R/CD127 expression is the hallmark of rheumatoid arthritis (RA) M1 macrophages and that these cells are highly responsive to interleukin-7 (IL-7)-driven osteoclastogenesis. We established that lipopolysaccharide (LPS), interferon-γ (IFNγ), and tumor necrosis factor-α (TNFα), the classic M1 macrophage mediators, enhance IL-7R expression in RA and murine macrophages. The local expression of IL-7 provokes arthritis, predominantly through escalating the number of F480

Indexed as

AnimalsArthritis, RheumatoidBone Marrow CellsCell DifferentiationHumansInterferon-gammaInterleukin-7LipopolysaccharidesMacrophagesMiceMice, Inbred C57BLMiddle AgedMyeloid CellsOsteoclastsReceptors, Interleukin-7Tumor Necrosis Factor-alphaInterferon-gammaInterleukin-7LipopolysaccharidesReceptors, Interleukin-7Tumor Necrosis Factor-alpha

Identifiers

PMID31197255
PMCPMC7331600
OpenAlexW2953031700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.